Clinical data | |
---|---|
Trade names | Regranex |
AHFS/ Drugs.com | Consumer Drug Information |
MedlinePlus | a699049 |
Routes of administration | Topical |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
(what is this?) (verify) |
Becaplermin (brand name Regranex) is a cicatrizant, available as a topical gel. Regranex is a human platelet-derived growth factor indicated along with good wound care for the treatment of lower extremity diabetic neuropathic ulcers. [1] It is also known as "platelet-derived growth factor BB". [1]
The drug is used for the treatment of diabetic foot ulcers. [2] Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and the ulcers healed on average 6 weeks faster. [3] Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care. [4]
The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator. [1] Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and was found to increase healing in patients with decreased healing capacity, such as people living with diabetes. [5]
Becaplermin must not be used at the site of a skin cancer. [6]
The most common side effects in clinical studies were erythematous rashes. [6]
A boxed warning has been added to the safety label to describe an increase rate of death from cancer when three or more tubes are used. [7] Regranex should be used with caution in patients with known malignancy. [1]